Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap, Robin L. Jones, Brian A. Van Tine, Bartosz Chmielowski, Anthony D. Elias, Douglas Adkins, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory Pennock, Meera R. Hameed, Gaurav D. Shah, Amy Qin, Ashwin Shahir, Damien M. Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz
Dive into the research topics of 'Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial'. Together they form a unique fingerprint.